This study is looking at whether a drug called dalcetrapib can reduce the risk of future heart problems in people who have recently had a heart attack (acute coronary syndrome or ACS). You could be eligible if you are at least 45 years old, have recently been hospitalized for ACS, and have a specific genetic marker called the AA genotype in the ADCY9 gene. This genetic marker will be checked with a special test. The study compares dalcetrapib (300 mg tablets) to a placebo (a pill with no medicine) to see if dalcetrapib can lower the chance of having another heart attack or a fatal heart event. The study aims to enroll 2000 participants, but its current status is unclear.

Study design

This is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to receive either dalcetrapib or a placebo, and neither you nor your doctor will know which you are receiving. It is a large study aiming for 2000 participants.

What's involved

You will have virtual or clinic visits every 3 months after randomization until the study ends. If you stop taking the study medication early, assessments will continue every 3 months.

Compensation

Not stated in the trial record.

Follow-up

The study will track your health until approximately 200 participants experience a primary event, with the main outcome measured at an average of 30 months from when you start.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.